Compounded tirzepatide cost a fraction of the brand, for now

For the last two years, the cheapest way onto a GLP-1 was almost never the pharmacy counter. Compounded tirzepatide cost a fraction of the brand, often a few hundred dollars a month against a list price north of a thousand, and millions of people took that deal. That window is closing. The FDA has pulled both tirzepatide and semaglutide off its shortage list, and the large-scale compounding that made the low price possible is being wound down.

What changed is worth walking through: what the drugs used to cost, what the brand vials cost now, and why the safety questions that trailed these compounded copies are worth taking seriously if you are still filling from a vial. Redose is a tracking and record-keeping tool, not medical advice, so treat everything below as background for a conversation with your prescriber.

What made compounded GLP-1 so cheap

During the shortage, federal law let pharmacies make their own copies. When the FDA lists a drug as in shortage, pharmacies operating under sections 503A and 503B may prepare a version of it. That is how compounding semaglutide and tirzepatide became a national business almost overnight, sold through telehealth sites, a local GLP-1 compounding pharmacy, or a med spa.

The math was simple. A compounder buys the active ingredient in bulk, mixes it with bacteriostatic water, and fills multi-dose vials. No branded pen, no injector, no list price. A semaglutide compound or a tirzepatide compound could sell for a tenth of what Novo Nordisk or Eli Lilly charged, which is the whole reason the category exploded.

• Buy the active ingredient from a bulk supplier
• Mix it with bacteriostatic water inside a vial
• Sell multi-dose vials through telehealth sites
• Skip the branded pen, injector and list price
• Price each month at a fraction of the brand

What compounded tirzepatide cost, and what it costs now

Prices varied by pharmacy, but the pattern held. Published compounded semaglutide prices clustered around $170 a month, with the cheapest tier under $100. Compounded tirzepatide cost a little more, commonly $200 to $400. Against a Wegovy list price near $1,350 a month, the yearly savings ran into five figures, and that was before insurance.

The brand response has narrowed the gap. In December 2025, Eli Lilly cut cash prices for Zepbound vials bought through LillyDirect to $299 to $449 a month depending on dose. Novo Nordisk sells Wegovy through NovoCare for roughly $199 to $349. Those are self-pay numbers, no insurance required, and they land within range of what a compounded vial used to cost.

At the median, a year of the compounded version ran about $2,000. A year of brand Wegovy at list ran closer to $16,000. That spread is why the market grew, and why it is shrinking now that brand vials sell for a few hundred a month.

The FDA pulled both drugs off the shortage list

The legal basis for mass compounding was the shortage itself, and the shortage is officially over. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and removed semaglutide on February 21, 2025. Once a drug leaves the list, compounders get a short wind-down and then have to stop.

The deadlines have already passed. Smaller 503A pharmacies had 60 days, and larger 503B outsourcing facilities had 90. A trade group sued to keep compounding alive, but the courts declined to block the FDA, so the dates held. In April 2026 the agency went further and proposed removing semaglutide, tirzepatide and liraglutide from the list of drugs eligible for bulk compounding at all, which is the part that makes today's access temporary.

Compounded drugs are not approved by FDA, the agency notes, and never went through the review for safety, potency and quality that brand drugs pass.

What survives is narrower. A 503A pharmacy can still compound for a specific patient when an approved product genuinely will not work, for example a documented allergy to an inactive ingredient. That is a real but small carve-out, not the tirzepatide compounding pharmacy pipeline that served millions.

Where the safety questions come from

Price was never the whole story. Regulators and both brand makers have flagged real problems with the compounded supply, and they are worth reading before you decide anything with your clinician.

Dosing errors and unit confusion

The FDA has reported overdoses where people gave themselves as much as 20 times the intended dose. The agency tied the errors to unfamiliarity with drawing medicine out of a vial, and to confusion between milligrams, milliliters and the units marked on an insulin syringe. A brand pen dials a dose. A semaglutide vial does not, so the number is yours to get right.

The FDA linked the overdoses to confusion between milligrams, milliliters and the unit marks on an insulin syringe, and to patients new to self injection.

Impurities, potency and additives

Eli Lilly's own testing of compounded tirzepatide found a reaction-related impurity in all ten samples it bought, roughly half of them below their labeled potency, plus bacterial contamination and endotoxin in some. Sellers had also mixed in extras like vitamin B12, glycine, pyridoxine and carnitine, none of which sit in the approved drug. And the salt forms some vendors used are chemically different from the semaglutide in Ozempic, which the FDA does not review for safety.

• Overdoses from mismeasured multi-dose vials
• Salt forms the FDA has never vetted for safety
• Impurities tied to added vitamin B12
• About half of tested samples below labeled potency
• Bacterial contamination found in some batches

What careful tracking looks like now

If you are staying on a compounded vial through the wind-down, or moving to a brand vial like Zepbound, the record-keeping matters more than it did with a pen. You are the one converting a milligram dose into units, rotating sites, and watching how much is left before a refill.

That is the quiet work a log is built for. A syringe unit calculator turns your prescribed milligrams and vial concentration into the exact units to draw, so the number is not a guess. A short reconstitution guide keeps the concentration consistent between vials. A dose log with reminders means a hectic week never becomes a doubled or a skipped dose.

• Calculate units from milligrams for every vial
• Log each dose the moment you inject it
• Rotate injection sites on a body map
• Track how many doses a vial has left
• Set a gentle reminder for the weekly dose

Compare your own notes against the trials, not against a stranger's post. Our semaglutide dosage chart shows how units map to milligrams, and the tirzepatide and semaglutide pages lay out what the published labels actually say.

Common questions about compounded GLP-1

Is compounded semaglutide safe?

It depends on the source, and even then the FDA has not reviewed it. Compounded products skip the agency's premarket check for safety, potency and sterility, and independent testing has turned up underdosed and contaminated batches. Anyone weighing it should talk to a prescriber, and when an approved product is available there is a strong reason to prefer it.

Is compounded tirzepatide still available in 2026?

Mostly not, at least not at scale. The mass-market tirzepatide compound sold by telehealth sites ended when the shortage did, and the April 2026 proposal would close the bulk route for good. A 503A pharmacy can still compound for an individual patient in narrow cases, but that is not the same as ordering a monthly vial online.

How much does compounded semaglutide cost versus the brand?

Compounded semaglutide historically ran about $170 a month, sometimes under $100. Brand self-pay has fallen to meet it, with Wegovy through NovoCare around $199 to $349 and Zepbound vials through LillyDirect at $299 to $449. The old five-figure yearly gap has shrunk to a few hundred dollars a month.

What do compounded semaglutide reviews actually tell you?

Compounded semaglutide reviews on forums and Reddit are useful for logistics and red flags, but they cannot vouch for what is in a given vial. Two people can order the same strength and receive different formulations, since additives and potency vary by pharmacy. Treat those posts as anecdote, and let your own tracked results and a clinician guide the plan.

Cheap compounded vials made the math easy to ignore, but the dose was always yours to get right, and that is truer now that people are switching pharmacies and formulations. Track every dose with confidence with Redose: get exact syringe units from the calculator, gentle reminders, injection site rotation, and a complete private log of your protocol. Get the app here: iOS.